Abstract: The present disclosure relates to a method for selecting mesenchymal stem cells having improved self-maintenance ability, wherein mesenchymal stem cells having excellent self-proliferative ability may be selected to reduce donor variation, and mesenchymal stem cells having excellent self-proliferative ability may be secured in large quantities and used for the development of cell therapy products.

Abstract: A method for culturing mesenchymal stem cells is disclosed. The method includes steps of: primary culturing mesenchymal stem cells in a medium containing umbilical cord blood serum; and subculturing the mesenchymal stem cells in a medium containing fetal bovine serum. The method for culturing mesenchymal stem cells may maintain stemness by reducing the differentiation and aging of stem cells, and in particular, may achieve a remarkably high proliferation rate.

Abstract: A cell death inhibitor including a mesenchymal stem cell genetically engineered to secrete growth-regulated oncogene-alpha (GRO-?) or overexpress GRO-? compared to a parent cell, GRO-?, or a combination thereof. A method of treating a muscle disease, including administering a pharmaceutically effective amount of a mesenchymal stem cell, which is genetically engineered to secrete growth-regulated oncogene-alpha (GRO-?) or overexpress GRO-? compared to a parent cell, or GRO-?, to a subject in need thereof.

Abstract: A method of culturing mesenchymal stem cells includes performing primary culture of umbilical cord-derived mesenchymal stem cells under hypoxic conditions with an oxygen partial pressure of 1 to 8% and pressure conditions of 1.0 to 8.0 PSI. The method of culturing umbilical cord-derived mesenchymal stem cells can maintain stemness by inhibiting the differentiation of stem cells and particularly can achieve a remarkably high proliferation rate.

Abstract: Provided are a composition for ciliogenesis, containing a mesenchymal stem cell or a culture medium of mesenchymal stem cell. The mesenchymal stem cell or the culture medium of mesenchymal stem cell increases the number and promotes growth of primary cilia in cells. The mesenchymal stem cell or the culture medium of mesenchymal stem cell can be used as a pharmaceutical composition for preventing or treating diseases caused by ciliopathy or ciliary impairment. The mesenchymal stem cell or the culture medium of mesenchymal stem cell can be used as a cosmetic composition. A method for preventing or treating ciliopathy or ciliary impairment is disclosed.

Abstract: The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.

Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used to treat or improve a pulmonary disease.

Abstract: Provided is a composition for preventing hair-loss and promoting hair growth, which contains, as an active ingredient, a conditioned media of stem cells stimulated by particular hair catagen inducers including TGF-?, a method of manufacturing the same, and methods of treatment thereof. In particular, disclosed is a use of the function of very effective hair growth by secreting Wnt3a, Bcl-2, CyclinD-1 and the like, which are known as signal transduction proteins.

Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used to treat or improve a pulmonary disease.

Abstract: A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema.

Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.

Abstract: Provided are a composition for preventing hair loss and stimulating hair growth, which includes small-sized stem cells, particularly, small-sized stem cells having a diameter of 8 ?m or less, or a culture thereof as an active ingredient, a method of preparing the same, and a use of the same. Provided is a use of the composition utilizing a hair growth stimulating function of the small-sized stem cells having a diameter of 8 ?m or less to considerably increase activity of hair follicle stem cells in a telogen phase.

Abstract: A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema.

Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.

Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.

Abstract: Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.

Abstract: Provided are a composition for preventing hair loss and stimulating hair growth, which includes small-sized stem cells, particularly, small-sized stem cells having a diameter of 8 ?m or less, or a culture thereof as an active ingredient, a method of preparing the same, and a use of the same. Provided is a use of the composition utilizing a hair growth stimulating function of the small-sized stem cells having a diameter of 8 ?m or less to considerably increase activity of hair follicle stem cells in a telogen phase.

Abstract: Provided is an a composition for preventing hair-loss and promoting hair growth containing as an active ingredient conditioned media of stem cells stimulated by particular hair catagen inducers including TGF-?, a method of manufacturing the same, and a use thereof. In particular, the present invention relates to a use of the function of very effective hair growth by secreting Wnt3a, Bcl-2, CyclinD-1 and the like, which are known as signal transduction proteins.

Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.

Abstract: Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.